bioRxiv Science⌕ Search

Biology subjects

Markovic, S. N.

Publications and source records attributed to Markovic, S. N..

3 recordsLinked to original sources

Integrative AI-Enabled Virtual Cell Modeling Reveals a Clinically Relevant Latent Effector State of Human CD8 T Cells Undetectable by Conventional Analyses

Understanding how immune checkpoint inhibitors (ICIs) reshape human T-cell responses requires models that move beyond static transcriptomic snapshots and discrete cell-state classifications. Here, we present an integrative AI-enabled virtual cell framework that represents human CD8 T-cell responses as dynamic and computable systems during ICI therapy. By integrating single-cell RNA sequencing with paired T-cell receptor sequencing within the C2S-scale foundation model, we construct a virtual representation of individual T cells, in which each cell is encoded by a unique functional identity that captures its transcriptional, signaling, and clonal characteristics. Using this framework, we identify a previously unrecognized dynamic latent effector state of CD8 T cells characterized by intermediate expression of effector genes, distinct signaling activity, and ongoing clonal expansion. Across independent patient cohorts, the virtual cell model consistently indicates that ICI therapy mainly acts by unmasking pre-existing effector potential rather than inducing de novo effector differentiation. Notably, this latent effector population remains transcriptionally restrained despite active signaling and clonal expansion, revealing a hidden reservoir of antitumor immune capacity. More broadly, our study demonstrates how AI-enabled virtual cell modeling can reconstruct latent cellular states and their dynamic transitions from multidimensional single-cell data. By incorporating functional identity into virtual cell model, this framework uncovers biologically meaningful yet non-obvious T-cell effector program during cancer immunotherapy and provides a generalizable approach for studying immune dynamics in human disease.

immunology↗

Proteomic analysis of exosomes from lymphatic affluents reveals their implications in developing premetastatic niche in melanoma.

Melanoma is an aggressive form of skin cancer that often spreads via lymphatic pathways to regional and distant sites. Melanoma-derived lymphatic exosomes play a crucial role in forming a tumor-supportive environment for metastasis, or premetastatic niche, within the first tumor draining lymph node, also known as the sentinel lymph node (SLN). Therefore, analyzing the proteomic content of tumor-draining lymphatic exosomes that deliver oncogenic molecules to the SLN is important in understanding the premetastatic niche. To reveal the proteomic landscape of lymphatic exosomes, we performed multidimension liquid chromatography-tandem mass spectrometry with multiplexing (18-samples) using tandem mass tag (TMT) labeling to profile the lymphatic exosomal proteomes obtained from afferent lymphatic channels leading to the SLN of patients with melanoma (n=6), control afferent lymphatic channels from prophylactic mastectomy (n=3) and non-cancer post-operative lymphatic fluid (n=9). Lymphatic fluid from postoperative lymphadenectomy drains served as another control to filter out non-melanoma alteration in lymph that may be related to the procedure of surgical resection and wound healing process. Our proteomic analysis identified 3929 proteins in the lymphatic exosomes, of which 968 were unique proteins absent from the current exosomal database. Interestingly, melanoma lymphatic exosomes possess distinctive proteomic cargo, which is significantly associated with cancer-associated and cellular structural remodeling pathways (FDR <0.05). Moreover, proinflammatory wound healing pathways are predominantly present in melanoma and postoperative lymph fluid compared to normal control afferent lymphatic channels. We identified a total of 17 uniquely modulated proteins in melanoma compared to control and postoperative lymph, which are critically involved in the process of melanoma tumorigenesis. At least ten upregulated proteins strongly correlate with each other at the gene expression levels in melanoma tumors compared to controls and may serve as a signature panel for melanoma (p = 2.13 x 10-58). In summary, this study represents the first comparative analysis of the lymphatic exosomal proteome and highlights distinct exosomal proteins that may support premetastatic niche formation in the SLN.

cancer biology↗

Peptide-binding groove contraction linked to the lack of T-cell response: Using complex structure and energy to identify neoantigens

Using personalized peptide vaccines (PPVs) to target tumor-specific non-self antigens (neoantigens) is a promising approach to cancer treatment. However, the development of PPVs is hindered by the challenge of identifying tumor-specific neoantigens, in part because current in silico methods for identifying such neoantigens have limited effectiveness. Here we report the results of molecular dynamics simulations of 12 oligopeptides bound with a human leukocyte antigen (HLA), revealing a previously unrecognized association between the inability of an oligopeptide to elicit a T-cell response and the contraction of the peptide-binding groove upon binding of the oligopeptide to the HLA. Our conformational analysis showed that this association was due to incompatibility at the interface between the contracted groove and its {beta}-T-cell antigen receptor (TCR). This structural demonstration that having the capability to bind HLA does not guarantee immunogenicity prompted us to develop an atom-based method [Formula] to predict immunogenicity through using the structure and energy of a peptide*HLA complex to assess the propensity of the complex for forming a ternary complex with its TCR. In predicting the immunogenicities of the 12 oligopeptides, [Formula] achieved a 100% success rate compared with success rates of 25-50% for 11 publicly available residue-based methods including NetMHC-4.0. While further validation and refinements of [Formula] are required, our results suggest a need to develop in silico methods that assess peptide characteristics beyond their capability to form stable binary complexes with HLAs to help remove hurdles in using the patient tumor DNA information to develop PPVs for personalized cancer immunotherapy.

immunology↗